Tyler Bonnett

Generating author description...

All published works

Action	Title	Year	Authors
+	Examining the bias-efficiency tradeoff from incorporation of nonconcurrent controls in platform trials: A simulation study example from the adaptive COVID-19 treatment trial	2025	Tyler Bonnett Gail E. Potter Lori E. Dodd
+ PDF Chat	Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE)	2022	Irini Sereti Kathryn Shaw‐Saliba Lori E. Dodd Robin Dewar Sylvain Laverdure Shawn T. Brown Olivier Tshiani Mbaya Jean Jacques Muyembe Tamfum Placide Mblala-Kingebeni Ydrissa Sow
+ PDF Chat	Endpoints for randomized controlled clinical trials for COVID-19 treatments	2020	Lori E. Dodd Dean Follmann Jing Wang Franz Koenig Lisa L. Korn Christian Schoergenhofer Michael A. Proschan Sally Hunsberger Tyler Bonnett Mat Makowski
+	Endpoints for randomized controlled clinical trials for COVID-19 treatments	2020	Lori E. Dodd Dean Follmann Jing Wang Franz Koenig Lisa L. Korn Christian Schoergenhofer Michael A. Proschan S. Hunsberger Tyler Bonnett Mat Makowski
+	Endpoints for randomized controlled clinical trials for COVID-19 treatments	2020	Lori E. Dodd Dean Follmann Jing Wang Franz Koenig Lisa L. Korn Christian Schoergenhofer Michael A. Proschan S. Hunsberger Tyler Bonnett Mat Makowski
+ PDF Chat	Knowing the Signs: A Direct and Generalizable Motivation of Two-Sided Tests	2019	Kenneth Rice Tyler Bonnett Chloe Krakauer

Common Coauthors

Coauthor	Papers Together
Lori E. Dodd	5
Lisa L. Korn	3
Yeming Wang	3
Dean Follmann	3
Franz Koenig	3
Thomas Jaki	3
Michael A. Proschan	3
Drifa Belhadi	3
Mat Makowski	3
Gail E. Potter	2
France Mentré	2
S. Hunsberger	2
Sally Hunsberger	2
Christian Schoergenhofer	2
Jing Wang	2
Bin Cao	2
Dehkontee Gayedyu-Dennis	1
Alexandre Delamo	1
Herman Kosasih Indonesia	1
Bin Cao	1
James T. Duworko	1
Bienvenu Salim Camara	1
Abdoul Habib Béavogui	1
Aaron Neal	1
Naranjargal Dashdorj	1
Naranbaatar Dashdorj	1
Iman Gulati	1
Christian Schoergenhofer	1
Seydou Samake	1
Djénéba Dabitao	1
Kevin Rubenstein	1
Muhammad Karyana	1
Mory Cherif Haidara	1
Laura A. McNay	1
Jamila Aboulhab	1
Seydou Doumbia	1
Ganbolor Jargalsaikhan	1
Renée Ridzon	1
Kenneth Rice	1
Kevin Newell	1
Shera Weyers	1
Moctar Tounkara	1
Shawn T. Brown	1
Dona Arlinda	1
Esther Akpa	1
Ratna Sardana	1
Abelardo Montenegro-Liendo	1
Olivier Tshiani Mbaya	1
Alyson Francis	1
Karine Fouth Tchos	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	A Proportional Hazards Model for the Subdistribution of a Competing Risk	1999	Jason P. Fine Malcolm H. Ray	2
+	Comparison of an ordinal endpoint to time-to-event, longitudinal, and binary endpoints for use in evaluating treatments for severe influenza requiring hospitalization	2019	Ross L Peterson David M. Vock Abdel Babiker John H. Powers Sally Hunsberger Brian Angus Armando Paez James D. Neaton	2
+	Measurement in clinical trials: A neglected issue for statisticians?	2009	Stephen Senn Steven A. Julious	2
+	A mixed‐effects multinomial logistic regression model	2003	Donald Hedeker	2
+	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19	2020	Nigel Stallard Lisa V. Hampson Norbert Benda Werner Brannath Thomas Burnett Tim Friede Peter Kimani Franz Koenig Johannes Krisam Pavel Mozgunov	2
+	Statistical Evidence: A Likelihood Paradigm	1998	Veronica J. Vieland Susan E. Hodge	1
+	I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy	2009	AD Barker C C Sigman Kelloff Gj NM Hylton DA Berry L. Esserman	1
+	The Effect of Sample Size on the Meaning of Significance Tests	1986	Richard M. Royall	1
+ PDF Chat	Testing and estimation in flexible group sequential designs with adaptive treatment selection	2005	Martin Posch Franz Koenig Michael Branson Werner Brannath Cornelia Dunger‐Baldauf Péter Bauer	1
+	Conclusions vs Decisions	1960	John W. Tukey	1
+ PDF Chat	Statistical significance tests.	1982	DR Cox	1
+	The Platform Trial	2015	Scott Berry Jason T. Connor Roger Lewis	1
+	Some recommendations for multi-arm multi-stage trials	2012	James Wason Dominic Magirr Martin Law Thomas Jaki	1
+ PDF Chat	Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial	2012	Matthew R. Sydes Mahesh Parmar Malcolm D. Mason Noel W. Clarke Claire Amos John Anderson Johann S. de Bono David P. Dearnaley John Dwyer Charlene Green	1
+	Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing	1995	Yoav Benjamini Yosef Hochberg	1
+ PDF Chat	Adding a treatment arm to an ongoing clinical trial: a review of methodology and practice	2015	D. Cohen Susan Todd Walter M. Gregory Julia Brown	1
+	False Discovery Rates: A New Deal	2016	Matthew Stephens	1
+ PDF Chat	The ASA Statement on <i>p</i>-Values: Context, Process, and Purpose	2016	Ronald L. Wasserstein Nicole A. Lazar	1
+	Choice of Column Scores for Testing Independence in Ordered 2 x K Contingency Tables	1987	Barry I. Graubard Edward L. Korn	1
+	Efficiencies of platform clinical trials: A vision of the future	2016	Benjamin R. Saville Scott Berry	1
+	Bayesian Decision Theory for Multiple Comparisons	2009	Charles Lewis Dorothy T. Thayer	1
+	Posterior Bayes Factors	1991	Murray Aitkin	1
+	Coherent Hypothesis Testing	2016	Victor Fossaluza Rafael Izbicki Gustavo Miranda da Silva Luís Gustavo Esteves	1
+ PDF Chat	Response‐adaptive designs for binary responses: How to offer patient benefit while being robust to time trends?	2017	Sofía S. Villar Jack Bowden James Wason	1
+ PDF Chat	Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both	2017	Janet Woodcock Lisa M. LaVange	1
+ PDF Chat	Redefine statistical significance	2017	Daniel J. Benjamin James O. Berger Magnus Johannesson Brian A. Nosek Eric‐Jan Wagenmakers Richard A. Berk Kenneth A. Bollen Björn Brembs Lawrence Brown Colin F. Camerer	1
+ PDF Chat	What Properties Might Statistical Inferences Reasonably be Expected to Have?—Crisis and Resolution in Statistical Inference	2018	G. K. Robinson	1
+	Optimal Statistical Decisions.	1971	D. V. Lindley Morris de Groot	1
+ PDF Chat	False discovery rates: a new deal	2016	Matthew Stephens	1
+ PDF Chat	Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols	2019	Jay Park Ellie Siden Michael J. Zoratti Louis Dron Ofir Harari Joel Singer Richard Lester Kristian Thorlund Edward J. Mills	1
+ PDF Chat	Including non-concurrent control patients in the analysis of platform trials: is it worth it?	2020	Kim May Lee James Wason	1
+ PDF Chat	Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats	2021	Kim May Lee Louise Brown Thomas Jaki Nigel Stallard James Wason	1
+ PDF Chat	Platform Trials — Beware the Noncomparable Control Group	2021	Lori E. Dodd Boris Freidlin Edward L. Korn	1
+	Rapidly increasing SARS-CoV-2 seroprevalence and limited clinical disease in three Malian communities: a prospective cohort study	2021	Issaka Sagara John Woodford Mamady Kone Mahamadoun H. Assadou Abdoulaye Katilé Oumar Attaher Amatigué Zéguimé M’Bouye Doucoure Emily Higbee Jacquelyn Lane	1
+ PDF Chat	Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Limited Clinical Disease in 3 Malian Communities: A Prospective Cohort Study	2021	Issaka Sagara John Woodford Mamady Kone Mahamadoun H. Assadou Abdoulaye Katilé Oumar Attaher Amatigué Zéguimé M’Bouye Doucoure Emily Higbee Jacquelyn Lane	1
+	Pre-pandemic SARS-CoV-2 serological reactivity in rural malaria-experienced Cambodians	2021	Jessica E. Manning Irfan Zaidi Chanthap Lon Luz Angela Rosas Jae-Keun Park Aiyana Ponce Jennifer A. Bohl Sophana Chea Maria Karkanitsa Sokunthea Sreng	1
+	How to Use and Interpret the Results of a Platform Trial	2022	Jay Park Michelle A. Detry Srinivas Murthy Gordon Guyatt Edward J. Mills	1
+	Bayes Factors	1995	Robert E. Kass Adrian E. Raftery	1
+ PDF Chat	A Theory of Some Multiple Decision Problems. II	1957	E. L. Lehmann	1
+ PDF Chat	A Theory of some Multiple Decision Problems, I	1957	E. L. Lehmann	1
+	Discrete Sequential Boundaries for Clinical Trials	1983	K. K. Gordon Lan David L. DeMets	1
+	Precision Promise (PrP): An adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC).	2022	Vincent J. Picozzi Anne‐Marie Duliège Eric A. Collisson Anirban Maitra Manuel Hidalgo Andrew Hendifar Gregory L. Beatty Sudheer Doss Lynn M. Matrisian Pamela S Herena	1
+ PDF Chat	On model-based time trend adjustments in platform trials with non-concurrent controls	2022	Marta Bofill Roig Pavla Krotka Carl‐Fredrik Burman Ekkehard Glimm Stefan M. Gold Katharina Hees Peter Jacko Franz Koenig Dominic Magirr Peter Mesenbrink	1
+	The Bayesian Time Machine: Accounting for temporal drift in multi-arm platform trials	2022	Benjamin R. Saville Donald A. Berry Nicholas Berry Kert Viele Scott Berry	1
+ PDF Chat	Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein	2022	Sarah Lapidus Feimei Liu Arnau Casanovas‐Massana Yile Dai John D. Huck Carolina Lucas Jon Klein Renata B. Filler Madison S. Strine Mouhamad Sy	1
+	Integrated likelihood methods for eliminating nuisance parameters	1999	James O. Berger Brunero Liseo Robert L. Wolpert	1
+ PDF Chat	On the use of non-concurrent controls in platform trials: a scoping review	2023	Marta Bofill Roig Cora Burgwinkel Ursula Garczarek Franz Koenig Martin Posch Quynh Nguyen Katharina Hees	1
+	A Bayesian Approach to Multiple Comparisons	1965	David B. Duncan	1
+ PDF Chat	Control of the mean number of false discoveries, Bonferroni and stability of multiple testing	2007	Alexander Gordon Galina Glazko Xing Qiu Andrei Yakovlev	1
+	A Decision-Theoretic Formulation of Fisher’s Approach to Testing	2010	Kenneth Rice	1